Business
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
Reproxalap Statistically Lower than Xiidra for the Two Endpoints of the Trial: Ocular Discomfort (p=0.002) and Ocular Itching (p=0.01) Results Consistent
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":"\n\nReproxalap Statistically Lower than Xiidra for the Two Endpoints of the Trial: Ocular Discomfort (p=0.002) and Ocular Itching (p=0.01)\n\n\nResults Consistent with Data from Post-Acute Ocular Tolerability Comparison of Reproxalap and Xiidra in Patients with Dry Eye Disease\n\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced positive top-line data from a Phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25% (reproxalap), an investigational new drug, versus Xiidra® (lifitegrast ophthalmic solution 5%) in patients with dry eye disease. Patient-reported ocular discomfort (p=0.002) and itching (p=0.01) were statistically lower with reproxalap than with Xiidra.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110006109/en/Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) on January 11, 2022 announced positive top-line data from a Phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25% (reproxalap), an investigational new drug, versus Xiidra® (lifitegrast ophthalmic solution 5%) in patients with dry eye disease. Patient-reported ocular discomfort (p=0.002) and itching (p=0.01) were statistically lower with reproxalap than with Xiidra®. (Graphic: Aldeyra Therapeutics)\n“The statistically significant symptom improvement of reproxalap over Xiidra observed in this trial reinforces the data from an earlier clinical trial demonstrating tolerability advantages of reproxalap over Xiidra in patients with dry eye disease,”1 stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. “The combination of rapid activity and improved tolerability evidenced by reproxalap in clinical testing has the potential to address significant compliance issues with currently available therapy, the median discontinuation rates of which are approximately one month.”2\n\n“The clinically relevant and statistically significant reduction in symptomatic activity suggest that reproxalap, if approved, has the potential to become a first-line therapy for the treatment of dry eye disease,” ...